08.14.2026

Drug and supplement producer Biofarm (stock symbol: BIO), which was recently acquired by Polish group Polpharma for RON1.3 billion, had a net profit of RON26.4 million in January-June 2026, down 46% more

08.06.2026

PwC Romania provided financial and tax due diligence services, as well as transaction support services, to the Polish pharmaceutical group Polpharma in connection with its acquisition of Biofarm, one more

07.21.2026

Polish pharmaceutical group Polpharma, which has recently acquired the Romanian drug manufacturer Biofarm in a deal valued at about EUR257 million, says that Romania is one of its strategic markets more

06.11.2026

Romania’s Financial Supervisory Authority (ASF) has officially approved the tender offer through which the Polish group Polpharma intends to acquire the whole of pharmaceutical manufacturer Biofarm more

05.06.2026

Pharmaceutical company Biofarm (BIO.RO) is to become subject to a voluntary tender offer (VTO) from Zakłady Farmaceutyczne Polpharma S.A, a Polish pharmaceutical producer. The announcement came from more

05.05.2026

Drug and supplement producer Biofarm ended the first quarter of 2026 with RON32.5 million net profit, up 0.6% from Q1/2025, despite smaller sales revenues and rising operational expenses. more

03.24.2026

The Board of Directors of drug manufacturer Biofarm (stock symbol: BIO) has convened the general meeting of shareholders on April 28 to vote on distributing dividends in the amount of RON41.4 million, more

02.12.2026

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) has sold a building on Iancu de Hunedoara Boulevard in downtown Bucharest to Iancu de Hunedoara Residence, for EUR5 million. more

01.13.2026

Drug manufacturer Biofarm Bucuresti wants to identify strategic opportunities supporting the company’s development plans, considering organic investments among others, but also identifying some more

11.14.2025

Drug manufacturer Biofarm (stock symbol: BIO) ended the first nine months of 2025 with a turnover of RON263.2 million, up 14% against the year-earlier period, and EBITDA climbed 16% to RON109 million. more

10.21.2025

Biofarm Bucuresti, one of the ten largest local drug manufacturers, has earmarked investments in its own drug brands, but also in new products it is set to launch on the market. more

08.18.2025

Drug manufacturer Biofarm (BIO.RO) posted sales revenue of RON162.9 million in the first half of 2025, up 15% from the same period in 2024, while net profit increased by 16% to RON48.8 million, more

06.23.2025

Biofarm, one of the leading pharmaceutical producers in Romania, which has two plants in Bucharest, plans to invest in retooling its first facility and develop a new research and development center, more

05.15.2025

Pharma producer Biofarm in the first quarter of 2025 registered sales revenues of RON95 million, up 33%, and RON32 million net profit, 57% above the Q1/2024 level. more

04.29.2025

Shareholders of pharmaceutical producer Biofarm (BIO.RO) approved at their general meeting on April 28 the distribution of the company's net profit of RON74.4 million for 2024, as per a report sent to more

03.20.2025

Pharmaceutical producer Biofarm (BIO.RO), has called shareholders for extraordinary and ordinary general meetings on April 29 to vote among others for the distribution of the RON74.4 million net more

11.14.2024

Pharmaceutical producer Biofarm Bucuresti (stock symbol: BIO) ended the first nine months of 2024 with net profit of RON73.25 million, at an individual level, up 4.7% from the same period of 2023, as more

08.22.2024

Pharmaceutical producer Biofarm Bucuresti (stock symbol: BIO) ended the first half of 2024 with net profit of RON42 million, down 17% from RON50.2 million reported in the same period of 2023, as per more

05.14.2024

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) ended the first three months of 2024 with net profit of RON20.6 million, down almost 35% from the same period of 2023, as per its quarterly financial more

04.24.2024

In their ordinary general meeting of April 24, the shareholders of pharmaceutical producer Biofarm Bucuresti (BIO.RO) approved, among others, the financial statements for 2023, the budget of revenue more

03.20.2024

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) has called shareholders to approve, among others, the distribution of RON30.5 million dividends from 2023 net profit. more

12.18.2023

Biofarm, a top five drug manufacturer locally, plans to expand on other foreign markets, both in and outside Europe. more

11.14.2023

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) announced in its financial report released on Nov 14 that its sales income grew by 9.7% on the year to RON229 million in the first nine months of more

10.05.2023

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) has informed the local capital market in a report about the decisions taken at the Extraordinary General Meeting of Shareholders of October 5, among more

09.12.2023

Pharmaceutical producer Biofarm Bucuresti (BIO.RO) has sold a plot of land to the company Iancu de Hunedoara Residence SRL for approximately EUR5 million. more